Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib and Letrozole in HR+/HER2- Breast Cancer (PROMETEO II)
NCT04130152Phase 1Completed
- Sponsor
- SOLTI
- Start
- Nov 2019
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of palbociclib in breast cancer, sponsored by SOLTI. Primary endpoint: Complete Cell Cycle Arrest at 4 weeks. Started Nov 2019; status: completed.
02
Drugs
palbociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04130152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04130152.